Celecoxib plays a multiple role to peripheral blood lymphocytes and anografts in acute rejection in rats after cardiac transplantation
Celecoxib plays a multiple role to peripheral blood lymphocytes and anografts in acute rejection in rats after cardiac transplantation作者机构：Department of Cardiac Surgery the First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China
出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)
年 卷 期：2009年第122卷第2期
页 面：188-192页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：celecoxib mitochondria apoptosis transplantation, heart
摘 要：Background Celecoxib, a selective cyclooxygenase-2 （COX-2） inhibitor, is a non-steroidal anti-inflammatory drug used as an adjuvant to sensitize cancer cells to apoptosis. However, in rats suffering from acute rejection, celecoxib reduced apoptosis of myocardial cells. We hypothesize that celecoxib reduces myocardial apoptosis either by inducing apoptosis in peripheral blood lymphocytes （PBLs） or by altering the percentage of CD4~ and CD8~ lymphocytes. Methods After cardiac transplantation, rats were administered intragastrically with celecoxib （50 mg/kg per day） for 3, 5 or 7 days, at which time the graft was excised and evaluated for organ rejection. In addition, PBLs were isolated from the blood to determine PBLs apoptosis, and the percentage of CD4＋ and CD8＋ lymphocytes. Results Celecoxib induced PBLs apoptosis in 3 days, but protected the cells from apoptosis at 5 and 7 days. Also, the percentage of CD4＋ lymphocytes decreased only at 3 days, but a reduction in the percentage of CD8＋ lymphocytes was not seen until 7 days after the transplant surgery. Celecoxib only decreased acute rejection at 5 days, with no discernible difference in rejection after 3 and 7 days. Conclusions The results suggested that celecoxib displayed a multiple physiological function in a time-dependent manner. Chin Med J 2009; 122（2）： 188-192
维普期刊数据库